



HeberFERON Basal cell carcinoma non-melanoma PUBLICATIONS

- Anasagasti-Angulo L, et al. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer. 2009;9:262. doi: 10.1186/1471-2407-9-262. Available in: <https://pubmed.ncbi.nlm.nih.gov/19643007/>.
- Vázquez-Blomquist D, et al. Selection of reference genes for use in quantitative reverse transcription PCR assays when using interferons in U87MG. Mol Biol Rep. 2012;39(12):11167-75. doi: 10.1007/s11033-012-2026-9. Available in: <https://pubmed.ncbi.nlm.nih.gov/23065266/>.
- Bello-Rivero I, et al. Development of a new formulation of interferons (HEBERPAG) for BCC treatment. J Cancer Res Ther. 2013;1:235- 43. doi:10.14312/2052-4994.2013-36. Available in: <https://www.nobleresearch.org/Doi/10.14312/2052-4994.2013-36>.
- Jiménez Y, et al. Uso de HeberPAG en carcinoma basocelular periocular. Rev Cub Oftalmol. 2014;27(3):482-9. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762014000300014&lng=es.
- García Y, et al. Retrospective Study of Periocular Non Melanoma Skin Cancer Treated with the Combination of IFN alpha2b and gamma (HeberPAG). J Clin Exp Ophthalmol. 2015;06. DOI: 10.4172/2155-9570.1000478. Available in: <https://www.longdom.org/open-access-pdfs/retrospective-study-of-periocular-non-melanoma-skin-cancer-treated-with-the-combination-of-ifn-alpha2b-and-gamma-heberpag-2155-9570-1000478.pdf>.
- Rojas I, et al. Administración del HEBERFERON en basocelular palpebral a propósito de dos casos. Bionatura. 2016;1(2):71-4. Disponible en <http://dx.doi.org/10.21931/RB/2016.01.02.6>. Available in: <https://www.revistabionatura.com/heberferon.html>.

- Anasagasti-Angulo L, et al. HeberFERON, formulation based on IFNs alpha2b and gamma for the treatment of non-melanoma skin cancer. Australasian Medical Journal. 2017;10(6):509-515. DOI: 10.21767/AMJ.2017.3013. Available in: https://www.researchgate.net/publication/318191920_HeberFERON_formulation_based_on_IFNs_alpha2b_and_gamma_for_the_treatment_of_non-melanoma_skin_cancer.
- Fernandez-Martori M, et al. Treatment of Basal Cell Carcinoma with Interferons Alpha-2b and Gamma in Primary Care. MEDICC Rev. 2018;20(1):11. doi: 10.37757/MR2018.V20.N1.4. Available in: <https://pubmed.ncbi.nlm.nih.gov/34229416/>.
- Bello-Rivero I. HeberFERON, a promising choice for the treatment of basal cell carcinoma. Integr Cancer Sci Therap. 2018;5(5): 1-2. DOI: 10.15761/ICST.1000292. Available in: <https://www.oatext.com/heberferon-a-promising-choice-for-the-treatment-of-basal-cell-carcinoma.php>.
- Bello-Rivero I, et al. HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment. Semin Oncol. 2018 Jan;45(1-2):27-33. doi: 10.1053/j.seminoncol.2018.04.007. Available in: <https://pubmed.ncbi.nlm.nih.gov/30318081/>.
- Sánchez Linares V, et al. Síndrome de Gorlin Goltz. A propósito de un caso. Gac Méd Espirit. 2018;20(3):136-145. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1608-89212018000300136&lng=pt.
- Negrín-Caceres Y, et al. Tratamiento del carcinoma basocelular periocular con una combinación sinérgica de interferones alpha-2b y gamma. Rev Mex Oftalmol. 2018;92(3):136-143. DOI: 10.24875/RMO.M18000029. Available in: <https://www.medigraphic.com/pdfs/revmexoft/rmo-2018/rmo183d.pdf>.

- Martínez-Suárez C, et al. Basal Cell Carcinoma Treated with HeberFERON. A Real World Retrospective Study. Clin Oncol. 2021;6:1872. Available in: <https://www.medrxiv.org/content/10.1101/2021.09.24.21263710v1>.
- Rojas I, et al. Respuesta clínica del tratamiento con HeberFERON en pacientes con carcinoma basal palpebral. Rev Cubana Oftalmol. 2021;34(1):e1139. Available in: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762021000100013.
- Sánchez Linares V, et al. HeberFERON en el carcinoma basocelular periocular. Serie de casos. Gac Méd Espirit. 2021;23(1). Disponible en: <https://revgmespirituana.sld.cu/index.php/gme/article/view/2248>.
- Rojas-Rondon I, et al. Safety of HeberFERON in patients with basal cell eyelid carcinoma. Rev Cubana Oftalmol. 2021;34(1):e1131. Available in: <https://www.medigraphic.com/pdfs/revcuboft/rco-2021/rco211k.pdf>.

